



# Morgan Stanley Healthcare Conference

September 12, 2022

**CAUTION CONCERNING FORWARD-LOOKING STATEMENTS:**

This document contains “forward-looking statements”—that is, statements related to future events that by their nature address matters that are, to different degrees, uncertain. For details on the uncertainties that may cause our actual future results to be materially different than those expressed in our forward-looking statements, see <https://www.ge.com/investor-relations/important-forward-looking-statement-information> as well as GE's annual reports on Form 10-K and quarterly reports on Form 10-Q. We do not undertake to update our forward-looking statements. This document also includes certain forward-looking projected financial information that is based on current estimates and forecasts. Actual results could differ materially.

**NON-GAAP FINANCIAL MEASURES:**

In this document, we sometimes use information derived from consolidated financial data but not presented in our financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP). Certain of these data are considered “non-GAAP financial measures” under the U.S. Securities and Exchange Commission rules. These non-GAAP financial measures supplement our GAAP disclosures and should not be considered an alternative to the GAAP measure. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in GE's SEC filings and earnings materials, as applicable.

GE's Investor Relations website at [www.ge.com/investor](http://www.ge.com/investor) and our corporate blog at [www.gereports.com](http://www.gereports.com), as well as GE's Facebook page and Twitter accounts, contain a significant amount of information about GE, including financial and other information for investors. GE encourages investors to visit these websites from time to time, as information is updated and new information is posted.

# Updates on Spin Progress



- Spin planned for first week of January 2023
- Announced GE HealthCare Board of Directors
- Investor Day to take place on December 8, 2022 in New York City
- GE HealthCare will be listed on Nasdaq with ticker "GEHC"

# Leading Global MedTech Innovator

Clear Strategy to Deliver Patient, Customer and Shareholder Value




## Precision Innovation

Connected care pathways and digitization of healthcare




## Growth Acceleration

Commercial capabilities and product leadership



## Business Optimization

Sustainable margin expansion and strong cash flow



*Leading innovator enabling personalized and precision health through integrated clinical care, connected technology, and data across patient journey*

## MARKET NEEDS

### Health system efficiency and access

- Demand for efficiency and flexibility where care is delivered
- Cost-effective products to increase access

### Improved outcomes

- Specific data insights to make informed decisions
- Advancements in diagnostics, monitoring, and therapeutics

### Digitization of health

- More precise diagnostics, better interoperability, improved workflow
- Seamless integration of artificial intelligence to improve outcomes

*Underpinned by more resilient, sustainable practices and products, while growing access to care*


# GE HealthCare: 2021 by the numbers



**1B+** Patients served



**48K** Employees



**\$18B** Revenue  
*~50% recurring*



**160** Countries served



**55%+** Revenue from outside U.S.



**4M+** Installed base



**16.7%** Reported margins



**>100%** FCF conversion\* -b)



**~\$1B** R&D

\* Non-GAAP Financial Measure: See GE IR website for reconciliations

(a- Service, PDX and Digital

(b- FCF conversion\*: segment FCF\* / segment net income, adjusted to include non-GAAP restructuring expense

# Industry leader in \$75B+ global healthcare sector with strong secular tailwinds



**Business Segments**



**Imaging**  
**\$10B**



**Ultrasound**  
**\$3B**



**Patient Care Solutions**  
**\$3B**



**Pharmaceutical Diagnostics**  
**\$2B**

**FY21 Revenue<sup>-a)</sup>**


**Enterprise Digital Solutions<sup>-b)</sup>**  
**\$1B**

**Service & Repair<sup>-c)</sup>**  
**\$6B**

***~50% Recurring Revenues***

(a) – Healthcare Systems includes Imaging, Ultrasound and Patient Care Solutions (PCS)  
(b) – Represents total Digital revenue included in HCS Imaging, Ultrasound and Patient Care Solutions figures above.  
(c) – Service & repair revenue included in HCS Imaging, Ultrasound and Patient Care Solutions figures above

# Where we deliver care along the patient journey



## GE's unique strengths

### Commitment to customers

- Major dept's in and out of hospital
- Addressing major disease states
- Deep engagement with KOLs

### Tackling major care areas

- Cardiology
- Oncology
- Neurology

### Technology leader

- A leader across modalities
- Digital/AI integration

### Strong growing franchise

- Long-term partnerships
- Best-in-class service

In Hospital

Community





## Precision Health Innovation

- Well-positioned given our products, leadership and execution capabilities to continue to break new ground in precision health

## Accelerating Growth

- Clear path to accelerate organic revenue growth structurally to mid-single digits

## Margin Expansion

- Executing on opportunities to improve operating model as a standalone company and expand margins to high-teens to 20%

## Sustainable Value Creation

- Focused on strong FCF generation, delivering long-term shareholder value

**A faster growing, more profitable company, driving superior long-term shareholder value creation**



GE HealthCare